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Aims Beta-blockers reduce morbidity and mortality in chronic heart failure (HF) patients with reduced ejection fraction.
However, there is heterogeneity in the response to these drugs, perhaps due to genetic variations in the b1-adren-
ergic receptor (ADRb1). We examined whether the Arg389Gly polymorphism in ADRb1 interacts with the dose
requirements of beta-blockers in patients with systolic HF.
Methods
and results
HF-ACTION was a randomized, multicentre trial of ambulatory HF patients with systolic dysfunction who were ran-
domized to exercise training or usual care. A subset of patients provided DNA. The relationships among beta-blocker
dose, ADRb1–389 genotype, and outcomes were assessed using the Cox proportional hazards regression model.
The interaction between beta-blocker dose and the ADRb1–389 genotype was tested. DNA information was avail-
able for 957 patients. The alleles did not deviate from Hardy–Weinberg equilibrium. Patients with the ADRb1–389
Arg/Arg genotype receiving low-dose beta-blockers had a two-fold increase in the risk of death compared with those
receiving a high dose (hazard ratio 2.09; P ¼ 0.015); this was not conferred in Gly carriers. There was also an inter-
action between improvements in Kansas City Cardiomyopathy Questionnaire score and beta-blocker dose by geno-
type, suggesting that higher doses of beta-blockade might be needed to achieve benefit in Arg/Arg genotype patients.
Conclusion There was a gene–dose interaction with the ADRb1–389 Arg/Arg vs. Gly carrier genotype and beta-blocker dose,
suggesting that patients with the Arg/Arg genotype might require a higher dose of beta-blockade to achieve a treat-
ment response similar to that of Gly carriers.
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Introduction
Heart failure is a global public health problem accounting for
. US$30 billion in total costs annually, and . 550 000 new
cases are diagnosed each year in the USA alone.1 – 5 Beta-blockers
have been shown to improve survival and reduce morbidity in
patients with heart failure; however, there is heterogeneity in
the response to these drugs.6– 8 One potential explanation for
this is that genetic variations in an individual patient’s profile may
contribute to the variability of response to beta-blockade.9 –17
The b1-adrenergic receptor (AR) gene (ADRb1) has a single
nucleotide polymorphism (SNP) encoding an arginine (Arg) or a
glycine (Gly) residue at position 389, which has been shown to
alter the molecular interaction of the b-receptor with the regula-
tory guanine nucleotide-binding proteins ( G-proteins) and acts as
a gain-of-function polymorphism.18,19 Specifically, the Arg389
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version of the human b1 AR is markedly different from the Gly
version; it has three to four times greater signal transduction cap-
acity and higher probability of being constitutively active, and it may
be more sensitive to the effects of inverse agonists.8,9,18,20,21 Given
the data suggesting that genetic polymorphisms in the ADRb1
gene may explain differences in individual beta-blocker therapeutic
responses, a critical question remains as to whether these genetic
variations may also influence the dose requirements of patients.
In the only study prospectively designed to test dose–response
relationships with the beta-blocker carvedilol, Bristow et al.
reported dose-related improvements in left ventricular ejection
fraction (LVEF) and survival.22 In the Metoprolol CR/XL Rando-
mized Intervention Trial in Congestive Heart Failure (MERIT-HF)
substudy, no dose–response relationship was observed for the
overall cohort, but a wide variation in dose response was observed
in patients.23 Few studies have evaluated a relationship between
genetic variations and beta-blocker dose requirements. One
study by McNamara et al. evaluated the angiotensin-converting
enzyme deletion allele variant and beta-blocker dose.24 In our
study, we aimed to assess whether a gene–dose interaction
exists between beta-blockers and the ADRb1–389Arg/Gly gene
variant.
The Heart Failure: A Controlled Trial Investigating Outcomes of
Exercise Training (HF-ACTION) trial was the largest study to test
the effects of exercise training vs. usual care in heart failure patients
with systolic dysfunction.25 HF-ACTION investigators collected
DNA from  1000 patients with thorough phenotypic character-
ization. This provided a large, well-treated contemporary heart
failure population in which to explore the relationship between
genetic variation and beta-blocker response. We examined
whether a pharmacogenetic interaction between the ADRb1–
389 polymorphism and dose requirements of beta-blockers
exists in patients with systolic heart failure. Because the
ADRb1–389 Arg/Arg receptor has demonstrated increased ad-
renergic activity, we hypothesized that patients with the Gly




The HF-ACTION trial design and outcomes have been described
previously.25 Briefly, HF-ACTION was a multicentre, randomized,
controlled trial testing the long-term safety and efficacy of aerobic ex-
ercise training plus evidence-based medical therapy vs. evidence-based
medical therapy alone in ambulatory outpatients with left ventricular
systolic dysfunction (LVEF ,35%) and New York Heart Association
(NYHA) class II– IV heart failure. Although not mandated, enrolment
criteria included patients who were on optimal heart failure therapy
according to American College of Cardiology/American Heart Associ-
ation and Heart Failure Society of America guidelines (including treat-
ment with beta-blocker therapy) or patients with a documented
rationale for variation (including intolerance, contraindication, patient
preference, or personal physician’s judgement). Patients were pre-
scribed a stable dose of beta-blocker for ≥ 6 weeks. Exclusion criteria
included an inability to exercise, regular aerobic exercise (more than
once per week), and a major cardiovascular event in the previous 6
weeks. The primary endpoint was the composite of all-cause death
or all-cause hospitalization. All-cause death was a pre-specified sec-
ondary endpoint. Patients were randomly assigned to usual care
alone (optimal medical therapy and a recommendation for regular
physical activity) or usual care plus a prescription of 36 sessions of
supervised aerobic exercise training at 60–70% of heart rate reserve
three times per week, followed by home-based training at the same in-
tensity five times per week. Patients were followed for a median of 2.5
years. Approximately 95% of patients were on a beta-blocker.
Events were adjudicated by an independent clinical events commit-
tee. This study complied with the Declaration of Helsinki; the relevant
institutional review boards, research ethics boards, and ethics commit-
tees of participating centres approved the study; and the coordinating
centre approved the protocol. An independent data and safety moni-
toring board appointed by the trial sponsor (the National Heart, Lung,
and Blood Institute) reviewed the protocol. All participants provided
informed consent.
A subset of patients enrolled in the HF-ACTION study agreed to
participate in the DNA substudy and provided blood collection at ran-
domization. Samples were stored at the Duke Center for Human Gen-
etics. Genomic DNA was isolated from whole blood using an
automated extractor (Qiagen Autopure). SNP genotyping was per-
formed using commercially available assays and kits (Applied Biosys-
tems TaqManw).
Statistical methods
Baseline characteristics were summarized by counts and percentages
for categorical variables and by medians with interquartile ranges for
continuous variables. Characteristics were compared between the
overall HF-ACTION cohort and the DNA cohort, and then
between Gly carriers (patients with the Gly/Gly or Gly/Arg genotype
at the ADRb1–389 receptor SNP) and Arg homozygotes (patients
with the Arg/Arg genotype at the ADRb1–389 receptor SNP)
among patients in the DNA cohort. For continuous variables, differ-
ences between Arg homozygotes and Gly carriers were tested for sig-
nificance using the analysis of variance (ANOVA) F-test when the
assumption of normality was satisfied; otherwise, the non-parametric
(NP) Kruskal–Wallis test was used. For categorical variables, the x2
test was used when the cell frequency was sufficient; otherwise,
exact tests (EXs) were used. A P-value ≤ 0.05 was considered statistic-
ally significant for all analyses.
The primary endpoint was all-cause mortality or all-cause hospital-
ization, and a secondary endpoint was all-cause mortality. The relation-
ship between these endpoints and beta-blocker dose and the
ADRb1–389 genotype was assessed using the Cox proportional
hazards regression model. Hardy–Weinberg equilibrium was assessed
for the candidate SNP using the x2 test. Due to evidence that patho-
physiology differs among Arg homozygotes vs. Gly carriers,18,19 the
analysis was conducted using a dominance model for the Gly allele.
Beta-blocker dose at baseline was standardized using carvedilol equiva-
lents and analysed discretely as low-dose (1–25 mg daily) vs. high-dose
(.25 mg daily) groups. Patients with zero dose or missing data were
excluded. To determine whether the impact of beta-blocker dose dif-
fered among Gly carriers and Arg homozygous patients, the inter-
action between beta-blocker dose and the ADRb1–389 genotype
was tested. For each endpoint, the regression analysis was adjusted
for clinical risk factors. Adjustment models were built using the ap-
proach described by O’Connor et al.26 but with a larger set of candi-
date variables.26 The clinical adjustment model for the primary
endpoint included Weber class, Kansas City Cardiomyopathy
Questionnaire (KCCQ) symptom stability, blood urea nitrogen,
region (USA vs. non-USA), LVEF, sex, mitral regurgitation (severe vs.
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non-severe), and ventricular conduction. The clinical adjustment model
for the secondary endpoint of all-cause mortality included exercise
duration, body mass index, creatinine, sex, loop diuretics dose, LVEF,
Canadian Cardiovascular Society angina classification, and ventricular
conduction. Because the ADRb1–389 genotype frequencies were
found to differ significantly by race, we also adjusted for self-reported
race. Adjusted Kaplan–Meier curves were plotted for each endpoint
by the ADRb1–389 genotype. If the interaction was significant, the
plots were examined for low vs. high beta-blocker dose separately.
Another secondary endpoint was quality of life, measured by
changes in KCCQ score at 3 and 12 months. For each time point,
the change in KCCQ score was summarized by medians with inter-
quartile ranges. Differences in KCCQ score change were compared
for the low vs. high beta-blocker dose groups using the rank sum
test. This comparison was performed overall and then among the
ADRb1–389 genotypes separately.
Additional analyses were conducted to examine the effects of
another common SNP in the b1 receptor, the Ser49Gly polymorphism
(referred to here as ADRb1–49). The analyses described above were
conducted with the substitution of ADRb1–49 to test whether there
was an interaction of this polymorphism with beta-blocker dose.
Statistical analysis was performed by the Duke Clinical Research In-
stitute using SAS software version 9.2 (SAS Institute, Cary, NC, USA).
Results
Evaluable DNA information was available for 957 patients. Of
those, 55 patients were not on a beta-blocker or did not have
dose information available; therefore, 902 patients were included
in this analysis. The alleles did not deviate from Hardy–Weinberg
equilibrium (P ¼ 0.82). Baseline characteristics are shown in
Table 1. There were no significant differences in clinical character-
istics between the Arg homozygous patients and Gly carriers
except for race (P , 0.01). The proportion of Gly carriers was
higher among black patients (22.8% Arg vs. 37.4% Gly) but lower
among white patients (73.5% Arg vs. 57.1% Gly). Overall, the
ADRb1–389 allele frequencies were 0.68 (Arg) and 0.32 (Gly),
with 0.72 (Arg) and 0.28 (Gly) in whites and 0.59 (Arg) and 0.41
(Gly) in blacks. These are consistent with previous studies
showing ADRb1–389 Arg allele frequencies of  0.73 in whites
and 0.58 in blacks.27
There was an equal distribution of Arg homozygous patients and
Gly carriers in the beta-blocker high-dose and low-dose groups,
and the median dose was the same in both genotypes (38 mg car-
vedilol equivalents daily). For the primary endpoint of all-cause
mortality or all-cause hospitalization, there was no significant inter-
action between the ADRb1–389 genotype and beta-blocker dose
(P ¼ 0.29). However, for the secondary endpoint of all-cause mor-
tality, there was a significant interaction between the ADRb1–389
genotype and beta-blocker dose in the model (P ¼ 0.04).
As shown in Table 2, patients with the ADRb1–389 Arg/Arg geno-
type receiving low-dose beta-blockers had a two-fold increase in
the risk of death compared with those receiving a high dose,
after adjusting for other important clinical variables [hazard ratio
(HR) 2.09; P ¼ 0.015]. There was no significant difference in risk
between patients receiving low- vs. high-dose beta-blocker (HR
0.91; P ¼ 0.73) among the Gly carriers. The adjusted Kaplan–
Meier curves for the two endpoints are shown in Figures 1 and 2.
Among the four genotype–dose groups, Arg/Arg patients on
low-dose beta-blocker had the highest event rate, which increased
over time. Specifically, the adjusted Kaplan–-Meier event rate at 2
years for Arg/Arg patients on low-dose beta-blockers was 14.4%
vs. 9.1% for those on a high dose.
Because the effect of the ADRb1 genotype on the outcome
could be confounded by differences in allele frequencies among
race, the analysis was repeated by race to determine if the findings
were consistent across populations. Although the interaction
between the ADRb1–389 genotype and beta-blocker dose was
no longer significant [probably due to the substantial decrease in
sample size for each subgroup analysis (P ¼ 0.06 for whites and
P ¼ 0.16 for blacks)], the pattern of results remained—we
observed an increased risk of death for Arg homozygous patients
on low- vs. high-dose beta-blockers and the ratio of HRs between
Arg homozygous patients and Gly carriers remained relatively
constant.
There was no significant difference in KCCQ score change at 3
and 12 months between low- and high-dose beta-blocker groups in
the overall cohort of patients in this analysis. However, Arg homo-
zygotes on high-dose beta-blockers experienced a significant im-
provement in their KCCQ scores at 3 months compared with
those on low-dose beta-blockers (P ¼ 0.04). Although the
median change in KCCQ score at 12 months in patients with
Arg homozygotes was higher for those on high-dose vs.
low-dose beta-blockers, the difference was no longer statistically
significant.
Unlike the ADRb1–389 analysis, the results of the ADRb1–49
analysis were non-significant. Specifically, the P-value for the
interaction between the ADRb1–49 genotype (Ser homozygotes
vs. Gly carriers) and beta-blocker dose (low vs. high) was 0.87
for the primary endpoint of all-cause mortality or all-cause
hospitalization and 0.69 for the endpoint of all-cause mortality.
Similar results were seen when repeating this analysis by race
(P-values ¼ 0.98 and 0.91 for whites and P-value ¼ 0.08 and 0.75
for blacks).
Discussion
There were several important findings from this analysis. First, for
patients on beta-blockers, there was a gene–dose interaction with
the ADRb1–389 genotype (Arg homozygous patients vs. Gly car-
riers) and beta-blocker dose ( ≤ 25 mg vs. .25 mg carvedilol
equivalents daily), suggesting that Arg homozygotes might
require a higher dose of beta-blockade to achieve a mortality
risk reduction similar to that of Gly carriers. In addition, there
was an interaction between improvements in KCCQ score at
3 months and beta-blocker dose by genotype, suggesting that
higher doses of beta-blockade might be needed to achieve
benefit in Arg homozygotes.
Our study showed that there was a genetic interaction with
beta-blocker dose when analysing the outcome of all-cause mortal-
ity. Several studies report differential response to beta-blocker
therapy based on the ADRb1–389 genotype for endpoints such
as exercise capacity, initial tolerability during beta-blocker titration,
changes in LVEF, and changes in left ventricular remodel-
ling.9,11,12,28 –30 Most of these studies had several limitations,
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Table 1 Baseline characteristics by DNA cohort and by ARDb1–389 genotype
Parameter HF-ACTION cohort (n 5 2331) Total DNA cohort (n 5 957) ARDb1 genotype
Arg/Arg (n 5 439) Gly carriers (n 5 518) P-valuea
Age, yearsb 2331, 59.3 (51.1, 68.0) 957, 58.7 (50.5, 67.5) 439, 59.7 (51.0, 67.9) 518, 58.0 (50.1, 67.0) 0.29 NP
Female sex, n (%) 661 (28.4) 284 (29.7) 118 (26.9) 166 (32.0) 0.08
Race, n (%) ,0.01
Black 749 (32.6) 290 (30.7%) 99 (22.8) 191 (37.4)
White 1426 (62.1) 611 (64.7) 319 (73.5) 292 (57.1)
Other 121 (5.3) 44 (4.7) 16 (3.7) 28 (5.5)
History of diabetes, n (%) 748 (32.1) 289 (30.2) 126 (28.7) 163 (31.5) 0.49
History of MI, n (%) 979 (42.0) 392 (41.0) 190 (43.3) 202 (39.0) 0.23
History of hypertension, n (%) 1388 (59.9) 574 (60.2) 268 (61.0) 306 (59.4) 0.41
Smoking status, n (%) 0.50
Never 866 (37.3) 350 (36.8) 156 (35.7) 194 (37.7)
Current 388 (16.7) 168 (17.6) 73 (16.7) 95 (18.4)
Past 1066 (45.9) 434 (45.6) 208 (47.6) 226 (43.9)
HF hospitalizations in previous 6 months, n (%) 0.60
0 1701 (73.6) 696 (73.3) 317 (72.9) 379 (73.7)
1 464 (20.1) 192 (20.2) 86 (19.8) 106 (20.6)
2 94 (4.1) 43 (4.5) 24 (5.5) 19 (3.7)
3 + 52 (2.3) 18 (1.9) 8 (1.8) 10 (1.9)
HF aetiology, n (%) 0.09
Ischaemic 1197 (51.4) 486 (50.8) 236 (53.8) 250 (48.3)
Non-ischaemic 1134 (48.6) 471 (49.2) 203 (46.2) 268 (51.7)
NYHA class, n (%) 0.65 EX
II 1477 (63.4) 635 (66.4) 298 (67.9) 337 (65.1)
III 831 (35.6) 317 (33.1) 139 (31.7) 178 (34.4)
IV 23 (1) 5 (0.5) 2 (0.5) 3 (0.6)
Mitral regurgitation, n (%) (moderate or severe) 256 (12.0) 115 (13.0) 55 (13.4) 60 (12.6) 0.70
Systolic BP, mmHgb 2327, 111.0 (100.0, 126.0) 956, 112.0 (1.00.0, 126.0) 438, 114.0 (102.0, 127.0) 518, 110.0 (100.0, 126.0) 0.16
Diastolic BP, mmHgb 2326, 70.0 (60.0, 78.0) 956, 70.0 (62.0, 78.5) 438, 70.0 (60.0, 78.0) 518, 70.0 (62.0, 80.0) 0.99 NP
Heart rate, b.p.m.b 2326, 70 (63.0, 77.0) 957, 70.0 (64.0, 77.0) 439, 70.0 (64.0, 77.0) 518, 70.0 (63.0, 77.0) 0.99 NP
Body mass indexb 2324, 29.9 (26.0, 35.1) 957, 29.9 (26.2, 35.2) 439, 29.6 (25.8, 34.9) 518, 30.3 (26.5, 35.4) 0.08 NP
LVEF, %b 2327, 24.7 (20.0, 30.1) 956, 24.8 (20.2, 30.1) 438, 24.9 (20.5, 30.0) 518, 24.6 (20.0, 30.2) 0.93 NP
Rest ECG ventricular conduction, n (%) 0.84
Normal 979 (43.1) 379 (40.2) 170 (39.1) 209 (41.2)
LBBB 379 (16.7) 166 (17.6) 81 (18.6) 85 (16.8)
RBBB 85 (3.7) 27 (2.9) 14 (3.2) 13 (2.6)
IVCD 292 (12.9) 142 (15.1) 68 (15.6) 74 (14.6)










primarily their limited power due to small sample sizes. One study
by Sehnert et al. of 637 patients on carvedilol or metoprolol
showed no differential effect by ADRb1–389 genotype on the
endpoint of transplant-free survival.28 Two large heart failure
trials with beta-blockers, MERIT-HF and the Beta-Blocker Evalu-
ation of Survival Trial (BEST), included DNA substudies that exam-
ined the ADRb1–389 Arg/Gly polymorphism and clinical
outcomes.9,31 The MERIT-HF trial’s DNA substudy of 600 patients
showed that morbidity or mortality were not differentially affected
by treatment with metoprolol CR/XL (controlled release/
extended release) by ADRb1–389 genotype. In contrast, the
BEST trial DNA substudy of 1040 patients showed that the
ADRb1–389 genotype signifianctly affected treatment response
to the beta-blocker bucindolol. However, bucindolol may have a
specific pharmacological profile, which confers a unique associ-
ation of the ADRb1–389 polymorphism with treatment response
in heart failure.8,32
The evidence for a dose–response relationship for cardiovascu-
lar drugs has been limited. The Multicenter Oral Carvedilol Heart
Failure Assessment (MOCHA) trial was the only study to examine
prospectively dose–response with beta-blockers in heart failure; it
demonstrated a positive dose–response relationship between
beta-blocker dose and LVEF improvement, as well as an improve-
ment in survival.22 However, given the small sample size, the sur-
vival findings were difficult to interpret. We recently showed
that in the HF-ACTION trial there was a significant relationship
between beta-blocker dose and outcomes.33 In the current
study, there did not appear to be a relationship between the
genetic polymorphism and the beta-blocker dose requirement in
terms of the primary combined endpoint of all-cause mortality
or all-cause hospitalization. However, when examining mortality
alone, Arg homozygotes had worse outcomes than Gly carriers
on lower doses of beta-blockade (P ¼ 0.015), but the benefit
was not different with higher doses of beta-blockade (P ¼ 0.17).
This may, in part, be explained by varied pharmacological activity
of the receptor in those patients with this genotype, given the
increased signalling capacity and higher probability of being consti-
tutively active than the Gly variant. Because of the mechanism of
action of metoprolol and carvedilol (neutral antagonists),8 it
could be postulated that a higher dose is needed to achieve antag-
onism. Adjusted Kaplan–Meier event rates were 14% for Arg/Arg
patients on low-dose beta-blockers vs. 9% for those on a high dose
at 2 years. The clinical implications could be substantial considering
the difference in the risk of events when higher doses are used
with genotyping for Arg homozygotes.
Another unique finding of this study that has not previously
been shown is the association of genetic variation and quality of
life, relative to beta-blocker dose. Beta-blockers have been
shown to improve quality of life,34 but the interaction between
genotype and beta-blocker dose has not been examined. Our
study suggests that in patients who are Arg homozygous, there
may be a greater improvement in quality of life with higher
doses of beta-blockade, compared with lower doses.
Limitations
Our findings should be considered in the context of several limita-
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patient cohort; however, this subpopulation was similar to the
overall HF-ACTION study cohort in terms of clinical characteris-
tics, and is one of the largest DNA substudies of ambulatory
patients with heart failure and reduced ejection fraction. Secondly,
this study analysed a patient population in which the majority of
patients received carvedilol or metoprolol. Our findings may not
apply to different types of beta-blockers used to treat patients
with heart failure. The current study was not a prospective evalu-
ation of beta-blocker dosing; thus, sicker patients may have
received lower doses due to an inability to tolerate higher doses.
Although we adjusted for numerous known predictors of
adverse outcomes, the possibility of important unidentified prog-
nostic indicators must be considered. Finally, although we
examined the most common coding SNP in the ADRb1 gene,
we cannot exclude the possibility that other SNPs in non-coding
regions or more extensive haplotypes not tested in this study
may be associated with beta-blocker response in heart failure.
Conclusions
Our study suggests there may be a differential dose requirement of
beta-blockers based on the ADRb1–389 Arg/Gly polymorphism.
Clinically, this could be used to identify patients who may
require titration to higher doses of beta-blockade. This supports
the concept of clinical trials and clinical practice moving from a
‘one-size-fits-all’ framework to individualized treatment based on
Figure 1 Adjusted Kaplan–Meier curves for primary endpoint by ADRb1–389 genotype. Adjusted for Weber class, Kansas City Cardiomy-
opathy Questionnaire symptom stability, blood urea nitrogen, region (USA vs. non-USA), left ventricular ejection fraction, sex, mitral regurgi-
tation (severe vs. non-severe), ventricular conduction, and race.
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Table 2 Relative risk of events for low- vs. high-dose beta-blocker by ADRb1–389 adrenergic receptor genotype
Outcome Total DNA cohort White cohort Black cohort
HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value
All-cause hospitalization or mortalitya
Interactionb 0.292 0.553 0.146
All-cause mortalityc
Interactionb 0.036 0.058 0.162
b1–389 AR genotype
Arg/Arg 2.09 1.16–3.78 0.015 2.50 1.26–4.93 0.008 4.81 0.71–32.70 0.108
Gly carrier 0.91 0.52–1.58 0.729 0.74 0.35–1.60 0.448 1.32 0.49–3.56 0.586
AR, adrenergic receptor; Arg, arginine; CI, confidence interval; Gly, glycine; HR, hazard ratio for low- vs. high-dose beta-blocker.
aAdjusted for Weber class, Kansas City Cardiomyopathy Questionnaire symptom stability, blood urea nitrogen, region (USA vs. non-USA), left ventricular ejection fraction, sex,
mitral regurgitation (severe vs. non-severe), ventricular conduction, and race (only in the total DNA cohort).
bb1–389 adrenergic receptor genotype by beta-blocker dose.
cAdjusted for exercise duration, body mass index, creatinine, sex, loop diuretics dose, left ventricular ejection fraction, Canadian Cardiovascular Society angina classification,
ventricular conduction, and race (only in the total DNA cohort).
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Figure 2 (A) Adjusted Kaplan–Meier curves for all-cause mortality for (A) low-dose beta-blocker and (B) high-dose beta-blocker by
ADRb1–389 genotype. (C) Adjusted Kaplan–Meier curves for all-cause mortality by beta-blocker and ADRb1–389 genotype. Adjusted for
exercise duration, body mass index, creatinine, sex, loop diuretics dose, left ventricular ejection fraction, Canadian Cardiovascular Society
angina classification, ventricular conduction, and race.
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genotyping. The ability to target appropriate doses of an agent
could improve outcomes while avoiding adverse events, allowing
optimization of the risk–benefit ratio for individual patients.
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